In this edition

SHINGRIX® VACCINE FOR FNHA CLIENTS ................................................................................................................................ 1
FINGOLIMOD COVERAGE CHANGES ....................................................................................................................................... 2
COLLABORATIVE PRESCRIBING AGREEMENTS: APREPITANT (EMEND®) AND NETUPITANT-PALONOSETRON (AKYNZEO®). 2
NON-BENEFIT(S) ...................................................................................................................................................................... 3

SHINGRIX® VACCINE FOR FNHA CLIENTS

Effective February 17, 2020, the Shingrix® vaccine is listed on the FNHA Supplementary Drug Formulary that is adjudicated through Pacific Blue Cross (PBC). When administered by a pharmacist to an FNHA client, a $10 administration fee may be claimed through PBC. Pharmacies can use the non-benefit PIN 66123642 in PharmaNet to claim the administration fee separately from the drug claim and ensure that the claim adjudicates through PBC.

See FNHA Shingrix® Coverage (PDF, 95 KB) for more information on processing a Shingrix claim.
FINGOLIMOD COVERAGE CHANGES

Recently, PharmaCare adjusted its coverage of fingolimod following the introduction of generic versions of the drug. The brand version, Gilenya®, is now a partial benefit under the Low Cost Alternative program, while full coverage is available only for the generic versions.

Due to its complexity and monitoring requirements, Gilenya had an associated Patient Support Program (PSP). Most of the generics offer similar programs. Unlike other drugs with PSPs (e.g., biologics), the switch from Gilenya to a generic may be initiated at the pharmacy. Switching to a generic fingolimod requires a change in the PSP provider, which can also be initiated at the pharmacy. Pharmacists are encouraged to enroll patients filling prescriptions for fingolimod in a PSP associated with the generic they are dispensing. For more information on PSPs for fingolimod, please contact the appropriate manufacturer:

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Contact Information</th>
</tr>
</thead>
</table>
Tel: 1 888 6-SANDOZ (726369) |
| PMS          | Email: [ally@patientassistance.ca](mailto:ally@patientassistance.ca) |
| Teva         | [Fingolimod Support](mailto:Fingolimod Support) |
| Apotex       | [www.apoassist.com](http://www.apoassist.com) |
| Marcan       | Tel: 1 844 918-0957  
Fax: 1 844 751-2446 |
| Mylan        | [www.mylan.ca](http://www.mylan.ca)  
Tel: 1 888 223-0038 |
| Taro         | [www.taro.ca](http://www.taro.ca)  
Tel: 1 833 618-0571 |

Patients who may have difficulty paying for the drug before they meet their Fair PharmaCare deductible should be made aware of the Monthly Deductible Payment Option.
COLLABORATIVE PRESCRIBING AGREEMENTS: APREPITANT (EMEND®) AND NETUPITANT-PALONOSETRON (AKYNZEO®)

In the November 26, 2019 (Edition 19-011) BC PharmaCare Newsletter, PharmaCare stated the Collaborative Prescribing Agreement (CPA) for aprepitant (Emend®) would be replaced by a CPA for netupitant-palonosetron (Akynzeo®).

Based on further consultation with BC Cancer, PharmaCare amended its decision such that prescribers will be able to prescribe either aprepitant or netupitant-palonosetron via CPA for the prevention of acute and delayed nausea and vomiting due to highly-emetogenic cancer chemotherapy.

The CPAs for prescribers who had been previously granted a CPA for aprepitant will be reactivated as of February 25, 2020. These prescribers do not need to send in Special Authority requests for aprepitant and do not need to reapply for an aprepitant CPA.

Oncologists and BC Cancer-designated oncology specialists who have no prior CPA are invited to apply for individual specialist exemption. Collaborative Prescribing Agreements for netupitant-palonosetron and aprepitant can be found on the Special Authority web pages for both drugs.

NON-BENEFITS

The following product PIN can be used in PharmaNet so the claim adjudicates through Pacific Blue Cross:

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>PIN</th>
<th>FORM</th>
<th>CRITERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shingrix® Injection Fee</td>
<td>66123642</td>
<td>Injection</td>
<td>FNHA clients aged 65 to 69</td>
</tr>
</tbody>
</table>

The following products have been reviewed and will not be listed as PharmaCare benefits under the DINs specified:

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>DIN</th>
<th>STRENGTH/FORM</th>
</tr>
</thead>
<tbody>
<tr>
<td>latanoprost (Monoprost®)</td>
<td>02456230</td>
<td>50 mg/ophthalmic solution</td>
</tr>
<tr>
<td>pegfilgrastim (Fulphila™)</td>
<td>02484153</td>
<td>10 mg/prefilled syringe</td>
</tr>
<tr>
<td>fluticasone propionate-salmeterol xinafoate (Aermony RespiClick™)</td>
<td>02467895</td>
<td>55 mcg/dry powder for inhalation</td>
</tr>
<tr>
<td></td>
<td>02467909</td>
<td>113 mcg/dry powder for inhalation</td>
</tr>
<tr>
<td></td>
<td>02467917</td>
<td>232 mcg/dry powder for inhalation</td>
</tr>
<tr>
<td>fluticasone propionate-salmeterol xinafoate (Arbesda RespiClick™)</td>
<td>02474611</td>
<td>55 mcg/14 mcg/dry powder for inhalation</td>
</tr>
<tr>
<td></td>
<td>02474638</td>
<td>113 mcg/14 mcg/dry powder for inhalation</td>
</tr>
<tr>
<td></td>
<td>02474646</td>
<td>232 mcg/14 mcg/dry powder for inhalation</td>
</tr>
</tbody>
</table>